Pipeline

At 858 Therapeutics, we are advancing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology. Our programs are focused on important nodes in cancer biology, including DNA damage repair, innate immunity, and RNA epigenetics. We leverage our deep expertise in structure-based drug discovery and translational research to develop differentiated drug candidates.

Target	Indication	Discovery	Preclinical	IND-enabling	Clinical	Rights
PARG	Solid tumors
QPCT/L	Neurodegeneration
METTL3	Solid tumors
ADAR1	Solid tumors

Target:

PARG

Indication:

Solid tumors

Discovery Preclinical IND-enabling Clinical

Rights:

Target:

QPCT/L

Indication:

Neurodegeneration

Discovery Preclinical IND-enabling Clinical

Rights:

Target:

METTL3

Indication:

Solid tumors

Discovery Preclinical IND-enabling Clinical

Rights:

Target:

ADAR1

Indication:

Solid tumors

Discovery Preclinical IND-enabling Clinical

Rights:

To learn more about partnering or licensing opportunities, please contact bd@8five8tx.com